#1 Clinical Trials Search in Europe

Festuca Pratensis Pollen Allergoid, Glutaraldehyde-Modified

This article discusses clinical trials investigating the use of Festuca Pratensis Pollen Allergoid, Glutaraldehyde-Modified, as part of a mixture of modified grass and tree pollen allergen extracts for treating allergic rhinitis, rhinoconjunctivitis, and mild asthma. These trials aim to assess the effectiveness and safety of subcutaneous immunotherapy using these modified allergen extracts compared to placebo in patients sensitized to grass and tree pollens.

Table of Contents

What is FESTUCA PRATENSIS POLLEN ALLERGOID, GLUTARALDEHYDE-MODIFIED?

FESTUCA PRATENSIS POLLEN ALLERGOID, GLUTARALDEHYDE-MODIFIED is a component of an allergy vaccine being studied for the treatment of grass and tree pollen allergies. It is part of a mixture that includes modified allergen extracts from various grass pollens and tree pollens (such as olive or juniper).[1] [2]

This treatment belongs to a class of medications called allergen extracts, which are used in immunotherapy to help reduce allergic reactions over time.

How Does It Work?

The treatment works through a process called immunotherapy. By exposing your body to small, controlled amounts of the allergens you’re sensitive to, your immune system can gradually learn to tolerate these substances without overreacting.[1] [2]

The allergens in this treatment are modified (changed) using a substance called glutaraldehyde. This modification helps to make the treatment safer and more effective by reducing the risk of severe allergic reactions while still allowing your immune system to recognize and adapt to the allergens.

What Conditions Does It Treat?

This treatment is being studied for people with:[1] [2]

  • Allergic rhinitis (hay fever): This is when your nose gets inflamed due to allergies, causing symptoms like sneezing, runny nose, and congestion.
  • Allergic rhinoconjunctivitis: This includes symptoms of both eye and nasal allergies.
  • Mild to moderate allergic asthma: When allergies trigger asthma symptoms like wheezing, coughing, and difficulty breathing.

Specifically, it’s designed for people who are allergic to grass pollens (like Festuca pratensis, Phleum pratense, and others) and certain tree pollens (like olive or juniper, depending on the specific mixture).

How Is It Administered?

The treatment is given as a subcutaneous injection, which means it’s injected just under the skin. Based on the clinical trial information, the treatment is typically administered over a period of about 12 months, with a maximum daily dose of 0.5 ml.[1] [2]

Current Clinical Trials

As of now, this treatment is being studied in Phase III clinical trials. These are large-scale studies that aim to confirm the effectiveness and safety of a treatment before it can be approved for widespread use.[1] [2]

The ongoing trials are testing the treatment in people aged 12-65 who have moderate to severe allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma, caused by grass and specific tree pollen allergies.

Effectiveness and Safety

The main goal of these clinical trials is to see how well the treatment works compared to a placebo (a dummy treatment with no active ingredients). Researchers are looking at several factors, including:[1] [2]

  • Overall reduction in allergy symptoms and need for other allergy medications
  • Number of symptom-free and medication-free days
  • Improvement in quality of life
  • Changes in the immune system’s response to the allergens
  • Safety and any side effects

Who Can Use This Treatment?

While the final guidelines for who can use this treatment will depend on the results of the clinical trials, the current studies give us some idea. Potential candidates include:[1] [2]

  • People aged 12-65
  • Those with moderate to severe allergic rhinitis or rhinoconjunctivitis
  • People with mild to moderate controlled asthma related to their allergies
  • Individuals who have a confirmed allergy to grass pollens and specific tree pollens (like olive or juniper)

However, there are also some factors that might prevent someone from using this treatment, such as severe asthma, certain other medical conditions, or pregnancy.

Potential Side Effects

As with any medical treatment, there may be side effects. The clinical trials are carefully monitoring for any adverse reactions. Some potential side effects of immunotherapy treatments like this can include:[1] [2]

  • Reactions at the injection site (redness, swelling, itching)
  • Mild allergy symptoms (sneezing, runny nose)
  • In rare cases, more severe allergic reactions

It’s important to note that the treatment is designed to be as safe as possible, and the clinical trials are closely monitoring all participants for any side effects.

Aspect Details
Study Type Phase III clinical trials
Design Prospective, multicentre, randomized, double-blind, placebo-controlled
Main Objective Evaluate clinical efficacy of subcutaneously administered polymerized allergen extracts vs placebo
Target Conditions Moderate-severe intermittent or persistent allergic rhinitis/rhinoconjunctivitis, with or without controlled mild-moderate asthma
Key Inclusion Criteria Ages 12-65, confirmed allergy history, positive skin prick test, specific IgE > 3.5 KU/L
Treatment Subcutaneous injections of modified allergen extracts including Festuca Pratensis Pollen Allergoid
Primary Endpoint Overall symptom and medication score during relevant pollen seasons
Secondary Endpoints Symptom-free days, medication-free days, asthma exacerbations, quality of life, immunological parameters
Safety Assessment Monitoring of adverse events, administration site reactions, and systemic reactions

FAQ

  • What is Festuca Pratensis Pollen Allergoid? Festuca Pratensis Pollen Allergoid is a modified allergen extract from meadow fescue grass pollen that has been treated with glutaraldehyde. This modification aims to reduce allergic reactions while maintaining the ability to desensitize the immune system.
  • What conditions are being treated in these clinical trials? The trials are focusing on treating moderate to severe intermittent or persistent allergic rhinitis and rhinoconjunctivitis, with or without mild to moderate controlled asthma, in patients sensitized to grass and tree pollens.
  • How is the treatment administered? The treatment is administered through subcutaneous injections, which means it's injected under the skin.
  • What is the main goal of these clinical trials? The main goal is to evaluate the clinical efficacy and safety of the polymerized allergen extracts, including Festuca Pratensis Pollen Allergoid, compared to placebo in reducing allergy symptoms and medication use.
  • Who can participate in these trials? Participants must be between 12 and 65 years old, have a confirmed history of allergic rhinitis or rhinoconjunctivitis (with or without mild asthma) caused by grass and specific tree pollens, and meet other inclusion criteria set by the researchers.

Ongoing Clinical Trials on Festuca Pratensis Pollen Allergoid, Glutaraldehyde-Modified

  • Study on the Effectiveness and Safety of a Grass and Juniperus Oxycedrus Allergy Vaccine for Patients with Allergic Rhinitis or Rhinoconjunctivitis with or without Mild Asthma

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effectiveness and Safety of a Grass and Olive Pollen Allergy Vaccine for Patients with Allergic Rhinitis or Asthma

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Allergoid: A modified form of an allergen that has been chemically altered to reduce its ability to cause allergic reactions while maintaining its effectiveness in immunotherapy.
  • Subcutaneous immunotherapy: A treatment method where allergen extracts are injected under the skin to gradually desensitize the immune system to specific allergens.
  • Rhinitis: Inflammation of the nasal passages, often resulting in symptoms such as sneezing, runny nose, and nasal congestion.
  • Rhinoconjunctivitis: A condition characterized by inflammation of both the nasal passages and the conjunctiva (the membrane covering the white part of the eye), typically causing symptoms in both the nose and eyes.
  • Polymerized allergen extracts: Allergen extracts that have been chemically modified to form larger molecules (polymers), which can help reduce allergic reactions while maintaining immunotherapeutic effects.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the investigational drug or treatment.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function used to assess the severity of asthma and other respiratory conditions.
  • ARIA classification: Allergic Rhinitis and its Impact on Asthma, a system used to classify the severity and duration of allergic rhinitis symptoms.
  • GEMA 5.0: Spanish Guidelines for Asthma Management, version 5.0, used to classify and guide the treatment of asthma.
  • Specific IgE: Immunoglobulin E antibodies that are specific to particular allergens, measured to diagnose allergies to specific substances.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-a-grass-and-juniperus-oxycedrus-allergy-vaccine-for-patients-with-allergic-rhinitis-or-rhinoconjunctivitis-with-or-without-mild-asthma/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-a-grass-and-olive-pollen-allergy-vaccine-for-patients-with-allergic-rhinitis-or-asthma/